Skip to main navigation Skip to search Skip to main content

Causal role of genetically predicted impairment of branched-chain amino acid catabolism on insulin secretion and insulin resistance in type 2 diabetes

Research output: Journal article publication › Journal article › Academic research › peer-review

Abstract

Background: Elevated branched-chain amino acids (BCAAs; leucine, valine, isoleucine) are linked to type 2 diabetes (T2D) risk, characterised by defective insulin secretion in pancreatic β-cell and peripheral insulin resistance. Causative interaction between BCAA metabolism and these two diabetic pathogenesis remains unclear. Methods: Using publicly available datasets from the European population, we conducted a meta-analysis of genome-wide association studies (GWAS), followed by multi-trait analysis of GWAS (MTAG), to identify genetic loci associated with BCAAs and their catabolites. Two-sample bidirectional Mendelian Randomisation (MR) examined putative causal associations of genetically determined BCAAs and their catabolites with 10 traits related to insulin and glucose metabolism. Sensitivity analyses evaluated robustness and specificity of observed associations. Results: MTAG identified 57.14%, 59.09%, and 63.41% novel genetic loci for circulating leucine, valine and isoleucine, respectively. Genetically elevated valine had a significant association with increased insulin fold change during oral glucose challenge test (OGTT) (β [95% CI] = 0.135 [0.045, 0.225]), False discovery rate adjusted p-value (pFDR = 0.022), and suggestive association with fasting glucose level (β [95% CI] = 0.031 [0.004, 0.058], inverse-variance weighted p-value [pIVW] = 0.025). In the reverse direction, genetically determined homeostasis model assessment of β-cell (HOMA-B) exhibited significant inverse associations with BCAAs (Leucine: β [95% CI] = −0.140 [−0.244, −0.036], pFDR = 0.034; Valine: β [95% CI] = −0.147 [−0.255, −0.040], pFDR = 0.030; Isoleucine: β [95% CI] = −0.149 [−0.248, −0.049], pFDR = 0.020). Moreover, β-hydroxyisovalerate, a leucine-derived catabolite, was inversely related to 2-h glucose level after OGTT (β [95% CI] = −0.149 [−0.227, −0.071], pFDR = 0.045). In the reverse direction, genetically predicted peak insulin response was suggestively associated with elevated isoleucine catabolite, 2-hydroxy-3-methylvalerate (β [95% CI] = 0.074 [0.018, 0.130], pIVW = 9.20 × 10−3). Conclusions: Our genetic analysis indicates BCAA catabolism and insulin secretion/action interact with each other; their aberrance might form a vicious cycle promoting T2D progression.

Original languageEnglish
Pages (from-to)3849-3860
Number of pages12
JournalDiabetes, Obesity and Metabolism
Volume28
Issue number5
DOIs
Publication statusPublished - 18 Feb 2026

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  1. SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well-being

Keywords

  • branched-chain amino acids (BCAAs)
  • genome-wide association study
  • insulin resistance
  • insulin secretion
  • Mendelian randomisation analysis
  • type 2 diabetes

ASJC Scopus subject areas

  • Internal Medicine
  • Endocrinology, Diabetes and Metabolism
  • Endocrinology

Fingerprint

Dive into the research topics of 'Causal role of genetically predicted impairment of branched-chain amino acid catabolism on insulin secretion and insulin resistance in type 2 diabetes'. Together they form a unique fingerprint.

Cite this